First human test of experimental cancer drug begins
NCT ID NCT06537310
Summary
This is an early-stage study to check the safety and find the right dose of a new drug called RO7567132. It is being tested alone and in combination with an existing immunotherapy drug (atezolizumab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to see how well the body tolerates the drug and how it behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
BC Cancer ? Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Clinica Universidad de Navarra Madrid
Madrid, 28027, Spain
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Kinghorn Cancer Centre
Darlinghurst, New South Wales, 2010, Australia
-
McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Rigshospitalet
København Ø, 2100, Denmark
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.